STK16

Summary

STK16 (serine/threonine kinase 16, HGNC:11394) is a protein-coding gene on chromosome 2q35, encoding Serine/threonine-protein kinase 16 (O75716). Membrane-associated protein kinase that phosphorylates on serine and threonine residues.

Predicted to enable protein serine/threonine kinase activity. Involved in protein autophosphorylation. Located in cytosol; nuclear body; and plasma membrane.

Source: NCBI Gene 8576 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 60 total — 1 likely-pathogenic
• Druggable target: yes — 35 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001330213

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11394
Approved symbol	STK16
Name	serine/threonine kinase 16
Location	2q35
Locus type	gene with protein product
Status	Approved
Aliases	MPSK1, PKL12, MPSK
Ensembl gene	ENSG00000115661
Ensembl biotype	protein_coding
OMIM	604719
Entrez	8576

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 12 protein_coding, 7 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000396738, ENST00000409260, ENST00000409516, ENST00000409638, ENST00000409743, ENST00000461417, ENST00000475342, ENST00000475696, ENST00000478018, ENST00000486813, ENST00000491697, ENST00000496443, ENST00000496800, ENST00000875262, ENST00000875263, ENST00000875264, ENST00000875265, ENST00000913739, ENST00000913740, ENST00000913741

RefSeq mRNA: 4 — MANE Select: NM_001330213 NM_001008910, NM_001330213, NM_001330214, NM_001330215

CCDS: CCDS42822, CCDS82573, CCDS86921

Canonical transcript exons

ENST00000396738 — 8 exons

Exon	Start	End
ENSE00001811654	219245479	219245796
ENSE00001819845	219248421	219250337
ENSE00003522107	219247415	219247535
ENSE00003575220	219248193	219248314
ENSE00003606757	219245896	219246085
ENSE00003624428	219247113	219247246
ENSE00003684484	219246657	219246876
ENSE00003692589	219247662	219247757

Expression profiles

Bgee: expression breadth ubiquitous, 192 present calls, max score 93.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.5476 / max 133.8733, expressed in 1808 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
25433	15.5476	1808

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	93.11	gold quality
body of pancreas	UBERON:0001150	92.73	gold quality
right lobe of liver	UBERON:0001114	92.72	gold quality
right adrenal gland cortex	UBERON:0035827	92.20	gold quality
islet of Langerhans	UBERON:0000006	92.18	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.12	gold quality
granulocyte	CL:0000094	92.00	gold quality
right adrenal gland	UBERON:0001233	91.99	gold quality
stromal cell of endometrium	CL:0002255	91.93	gold quality
body of stomach	UBERON:0001161	91.85	gold quality
left adrenal gland cortex	UBERON:0035825	91.50	gold quality
left adrenal gland	UBERON:0001234	91.40	gold quality
right testis	UBERON:0004534	91.38	gold quality
left testis	UBERON:0004533	91.34	gold quality
right lobe of thyroid gland	UBERON:0001119	90.92	gold quality
transverse colon	UBERON:0001157	90.80	gold quality
left lobe of thyroid gland	UBERON:0001120	90.57	gold quality
lower esophagus mucosa	UBERON:0035834	90.55	gold quality
adenohypophysis	UBERON:0002196	90.43	gold quality
metanephros cortex	UBERON:0010533	90.41	gold quality
apex of heart	UBERON:0002098	90.19	gold quality
rectum	UBERON:0001052	90.14	gold quality
minor salivary gland	UBERON:0001830	90.02	gold quality
pancreas	UBERON:0001264	89.93	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.76	gold quality
prefrontal cortex	UBERON:0000451	89.75	gold quality
lower esophagus	UBERON:0013473	89.72	gold quality
lower esophagus muscularis layer	UBERON:0035833	89.72	gold quality
gall bladder	UBERON:0002110	89.66	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	89.42	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

86 targeting STK16, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-4658	99.77	64.94	514
HSA-MIR-6790-5P	99.77	65.24	505
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-3659	99.70	67.97	694
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-1224-5P	99.48	65.59	803
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-516A-3P	99.46	67.96	1378

Literature-anchored findings (GeneRIF, showing 6)

• The Endogenous STK16 subcellular localization was evaluated by indirect immunofluorescence in NRK cells, demonstrating a Golgi-associated pattern that appears to be independent of signals provided by integrin pathways. (PMID:16310770)
• MAL2 and STK16 function to sort secretory soluble cargo into the constitutive secretory pathway in hepatocytes. (PMID:25084525)
• we revealed STK16 as a novel actin binding protein that resides in the Golgi, which regulates actin dynamics to control Golgi structure and participate in cell cycle progression. (PMID:28294156)
• Exosomes from M1-polarized macrophages promote apoptosis in lung adenocarcinoma via the miR-181a-5p/ETS1/STK16 axis. (PMID:35092121)
• STK16 promoted colorectal cancer progress in a c-MYC signaling-dependent manner. (PMID:38622518)
• Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer. (PMID:38723720)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	stk16	ENSDARG00000037777
mus_musculus	Stk16	ENSMUSG00000026201
rattus_norvegicus	Stk16	ENSRNOG00000019294
drosophila_melanogaster	CG1227	FBGN0037491

Paralogs (2): AAK1 (ENSG00000115977), BMP2K (ENSG00000138756)

Protein

Protein identifiers

Serine/threonine-protein kinase 16 — O75716 (reviewed: O75716)

Alternative names: Myristoylated and palmitoylated serine/threonine-protein kinase, Protein kinase PKL12, TGF-beta-stimulated factor 1, Tyrosine-protein kinase STK16, hPSK

All UniProt accessions (4): B4DPS1, O75716, B8ZZI5, B8ZZN3

UniProt curated annotations — full annotation on UniProt →

Function. Membrane-associated protein kinase that phosphorylates on serine and threonine residues. In vitro substrates include DRG1, ENO1 and EIF4EBP1. Also autophosphorylates. May be involved in secretory vesicle trafficking or intracellular signaling. May have a role in regulating stromal-epithelial interactions that occur during ductal morphogenesis in the mammary gland. May be involved in TGF-beta signaling. Able to autophosphorylate on Tyr residue; it is however unclear whether it has tyrosine-protein kinase toward other proteins.

Subunit / interactions. Monomer. Interacts with DRG1 (via its N-terminal); the interaction phosphorylates DRG1.

Subcellular location. Cytoplasm. Perinuclear region. Membrane.

Tissue specificity. Ubiquitously expressed at very low levels.

Post-translational modifications. Mainly autophosphorylated on serine/threonine residues. Also autophosphorylated on Tyr-198. It is uncertain whether palmitoylation is on Cys-6 and/or Cys-8.

Similarity. Belongs to the protein kinase superfamily. Ser/Thr protein kinase family.

RefSeq proteins (4): NP_001008910, NP_001317142, NP_001317143, NP_001317144 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR052239	Ser/Thr-specific_kinases	Family

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.1 — non-specific serine/threonine protein kinase (BRENDA: 71 organisms, 682 substrates, 228 inhibitors, 23 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0007–0.64	11
KKRAARATSNVFA	0.013–0.045	3
PAH1 PHOSPHATIDATE PHOSPHATASE	0.0002	2
RRRLSSLRA	0.0036–0.0037	2
GTP	0.46	1
KKRAARASSNVFA	0.02	1
LYS-LYS-PHE-ASN-ARG-THR-LEU-SER-VAL-ALA	0.0093	1
MYELIN BASIC PROTEIN	0.145	1

Catalyzed reactions (Rhea), 3 shown:

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)
• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (52 total): helix 13, strand 11, sequence variant 5, sequence conflict 5, lipid moiety-binding region 3, mutagenesis site 3, modified residue 3, turn 2, binding site 2, initiator methionine 1, chain 1, domain 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2BUJ	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75716-F1	93.41	0.88

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 148 (proton acceptor)

Ligand- & substrate-binding residues (2): 26–34; 49

Post-translational modifications (6): 2, 6, 8, 185, 197, 198

Mutagenesis-validated functional residues (3):

Position	Phenotype
2	loss of myristoylation.
6	loss of palmitoylation.
8	loss of palmitoylation.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 100 (showing top): RNGTGGGC_UNKNOWN, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, GOCC_GOLGI_ASSOCIATED_VESICLE, CREB_Q2_01, GOBP_RESPONSE_TO_GROWTH_FACTOR, USF_02, HAMAI_APOPTOSIS_VIA_TRAIL_DN, GOBP_PROTEIN_AUTOPHOSPHORYLATION, GOMF_PROTEIN_KINASE_ACTIVITY, GOMF_KINASE_ACTIVITY, GOMF_NON_MEMBRANE_SPANNING_PROTEIN_TYROSINE_KINASE_ACTIVITY, TCANNTGAY_SREBP1_01, GOMF_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOMF_ADENYL_NUCLEOTIDE_BINDING

GO Biological Process (4): positive regulation of transcription by RNA polymerase II (GO:0045944), protein autophosphorylation (GO:0046777), cellular response to transforming growth factor beta stimulus (GO:0071560), protein phosphorylation (GO:0006468)

GO Molecular Function (11): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), protein serine/threonine kinase activity (GO:0004674), non-membrane spanning protein tyrosine kinase activity (GO:0004715), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein tyrosine kinase activity (GO:0004713), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (9): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), Golgi-associated vesicle (GO:0005798), cytosol (GO:0005829), plasma membrane (GO:0005886), nuclear body (GO:0016604), perinuclear region of cytoplasm (GO:0048471), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
protein kinase activity	3
cytoplasm	3
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
protein phosphorylation	1
cellular response to growth factor stimulus	1
response to transforming growth factor beta	1
phosphorylation	1
protein modification process	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
protein tyrosine kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
nuclear lumen	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cytoplasmic vesicle	1
membrane	1
cell periphery	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1105 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STK16	NPPC	P23582	651
STK16	UGT2B7	P16662	548
STK16	DRG1	Q9Y295	526
STK16	GCK	P35557	491
STK16	CSNK1G1	Q9HCP0	467
STK16	HNF1A	P20823	455
STK16	FOXH1	O75593	434
STK16	LHX3	Q9UBR4	426
STK16	SERPINE1	P05121	424
STK16	SRSF1	Q07955	400
STK16	RIOK1	Q9BRS2	393
STK16	GATA5	Q9BWX5	389
STK16	ACIN1	Q9UKV3	389
STK16	PCBD1	P61457	386
STK16	SLCO1A2	P46721	384

IntAct

435 interactions, top by confidence:

A	B	Type	Score
STK16	KCTD17	psi-mi:“MI:0915”(physical association)	0.780
KCTD17	STK16	psi-mi:“MI:0915”(physical association)	0.780
TRIM42	STK16	psi-mi:“MI:0915”(physical association)	0.720
SAXO1	STK16	psi-mi:“MI:0915”(physical association)	0.720
EFEMP2	STK16	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-8	STK16	psi-mi:“MI:0915”(physical association)	0.720
INCA1	STK16	psi-mi:“MI:0915”(physical association)	0.720
STK16	PLSCR3	psi-mi:“MI:0915”(physical association)	0.720
STK16	EFEMP2	psi-mi:“MI:0915”(physical association)	0.720
STK16	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
STK16	INCA1	psi-mi:“MI:0915”(physical association)	0.720
PLSCR3	STK16	psi-mi:“MI:0915”(physical association)	0.720
RPIA	STK16	psi-mi:“MI:0915”(physical association)	0.670
MIIP	STK16	psi-mi:“MI:0915”(physical association)	0.670
KCTD14	STK16	psi-mi:“MI:0915”(physical association)	0.670
STK16	MIIP	psi-mi:“MI:0915”(physical association)	0.670
STK16	KCTD14	psi-mi:“MI:0915”(physical association)	0.670
STK16	RPIA	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (182): STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), STK16 (Two-hybrid), DNAJA3 (Two-hybrid), CALCOCO2 (Two-hybrid)

ESM2 similar proteins: A0A5B9GBF0, A1CPG7, A1D2C9, A1IVT7, A2BD05, A2QRF6, B0XR80, D3ZBE5, G1XJZ4, G5EDF7, G5EFM9, M1T7M3, O09110, O75716, O88697, P0CP69, P21708, P26696, P27361, P28482, P45985, P46196, P46734, P47809, P52564, P57760, P59895, P70236, Q0D0P5, Q0U4L8, Q1DUU8, Q1KTF2, Q2WFL5, Q4PC06, Q4W6D3, Q4WSF6, Q52PH6, Q56R42, Q5E9X2, Q63844

Diamond homologs: A0QNG1, A5D791, A5GFW1, A5TY84, A5U3A3, A5U3A6, A8XJQ6, B0BBT2, O14965, O75716, P0A5S5, P0DPS8, P0DPS9, P18652, P33973, P38070, P41808, P53599, P53739, P54666, P54737, P54744, P57760, P57993, P59241, P9WI70, P9WI71, P9WI74, P9WI75, P9WI76, P9WI77, P9WI78, P9WI79, P9WI80, P9WI81, Q04J43, Q0WPH8, Q255D2, Q2TA06, Q3KM61

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
STK16	unknown	STK16	phosphorylation
STK16	unknown	DRG1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 77 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	10	12.7×	1e-06

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of gene expression	7	7.8×	1e-02
protein phosphorylation	7	7.7×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	47
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2578200	NM_006000.3(TUBA4A):c.313C>T (p.Arg105Cys)	Likely pathogenic

SpliceAI

1346 predictions. Top by Δscore:

Variant	Effect	Δscore
2:219245891:TCCA:T	acceptor_loss	1.0000
2:219245894:A:AC	acceptor_loss	1.0000
2:219245894:A:AG	acceptor_gain	1.0000
2:219245894:AGCAT:A	acceptor_gain	1.0000
2:219245895:G:GG	acceptor_gain	1.0000
2:219245895:GC:G	acceptor_gain	1.0000
2:219245895:GCA:G	acceptor_gain	1.0000
2:219245895:GCAT:G	acceptor_gain	1.0000
2:219245895:GCATG:G	acceptor_gain	1.0000
2:219246049:A:AG	donor_gain	1.0000
2:219246081:GAGGG:G	donor_gain	1.0000
2:219246083:GGG:G	donor_gain	1.0000
2:219246084:GGG:G	donor_gain	1.0000
2:219246647:T:TA	acceptor_gain	1.0000
2:219246655:A:AG	acceptor_gain	1.0000
2:219246655:AGT:A	acceptor_gain	1.0000
2:219246655:AGTG:A	acceptor_gain	1.0000
2:219246656:G:GG	acceptor_gain	1.0000
2:219246656:GT:G	acceptor_gain	1.0000
2:219246656:GTG:G	acceptor_gain	1.0000
2:219246656:GTGG:G	acceptor_gain	1.0000
2:219246835:GGTGC:G	donor_gain	1.0000
2:219246836:GTGC:G	donor_gain	1.0000
2:219246837:TGCT:T	donor_gain	1.0000
2:219247411:ACAG:A	acceptor_loss	1.0000
2:219247412:CA:C	acceptor_loss	1.0000
2:219247413:A:AG	acceptor_gain	1.0000
2:219247413:AG:A	acceptor_loss	1.0000
2:219247414:G:GG	acceptor_gain	1.0000
2:219247414:G:GT	acceptor_loss	1.0000

AlphaMissense

2001 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:219246717:G:C	K49N	1.000
2:219246717:G:T	K49N	1.000
2:219246661:T:C	F31L	0.999
2:219246663:C:A	F31L	0.999
2:219246663:C:G	F31L	0.999
2:219247417:A:C	D148A	0.999
2:219247417:A:T	D148V	0.999
2:219247418:C:A	D148E	0.999
2:219247418:C:G	D148E	0.999
2:219247424:G:C	K150N	0.999
2:219247424:G:T	K150N	0.999
2:219247435:T:A	I154K	0.999
2:219247471:A:T	D166V	0.999
2:219247472:C:A	D166E	0.999
2:219247472:C:G	D166E	0.999
2:219247696:G:C	R199P	0.999
2:219247755:T:A	W219R	0.999
2:219247755:T:C	W219R	0.999
2:219248479:C:A	R280S	0.999
2:219246713:T:C	L48P	0.998
2:219246715:A:G	K49E	0.998
2:219246716:A:T	K49M	0.998
2:219247417:A:G	D148G	0.998
2:219247422:A:G	K150E	0.998
2:219247433:T:A	N153K	0.998
2:219247433:T:G	N153K	0.998
2:219247471:A:C	D166A	0.998
2:219247684:C:T	T195I	0.998
2:219247708:T:C	L203P	0.998
2:219248200:G:A	G222D	0.998

dbSNP variants (sampled 300 via entrez): RS1000543493 (2:219245719 T>A,G), RS1001526126 (2:219247436 A>G), RS1002031647 (2:219246041 C>G,T), RS1002200789 (2:219245260 C>G), RS1003527769 (2:219250272 A>G), RS1003768201 (2:219247832 T>C), RS1003784936 (2:219243539 A>C), RS1003968493 (2:219250021 ACTC>A), RS1004033258 (2:219248897 G>A,T), RS1004510956 (2:219249095 G>C), RS1004566261 (2:219244287 C>T), RS1005329205 (2:219243734 T>C), RS1005497649 (2:219249706 A>T), RS1005798711 (2:219249979 G>A,C), RS1006116968 (2:219250269 G>A)

Disease associations

OMIM: gene MIM:604719 | disease phenotypes: MIM:616208, MIM:621226

GenCC curated gene-disease

Mondo (2): amyotrophic lateral sclerosis type 22 (MONDO:0014531), spastic ataxia 11, autosomal dominant (MONDO:0979230)

Orphanet (1): Amyotrophic lateral sclerosis (Orphanet:803)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST90002385_463	High light scatter reticulocyte count	2.000000e-11
GCST90002386_534	High light scatter reticulocyte percentage of red cells	2.000000e-12
GCST90002405_4	Reticulocyte count	1.000000e-10
GCST90002406_71	Reticulocyte fraction of red cells	4.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007986	reticulocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3938 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

35 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 188,381 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1078178	MOMELOTINIB	4	3,481
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1289926	AXITINIB	4	15,732
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL189963	PALBOCICLIB	4	13,102
CHEMBL2035187	PACRITINIB	4	3,345
CHEMBL2103830	FOSTAMATINIB	4	3,841
CHEMBL3301610	ABEMACICLIB	4	7,045
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL3622821	UPADACITINIB	4	2,726
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL300138	ENZASTAURIN	3	3,209
CHEMBL3137331	DEFACTINIB	3	1,229
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1721885	SU-014813	2	363
CHEMBL230011	TG100-115	2	1,504
CHEMBL402548	DANUSERTIB	2
CHEMBL475251	R-406	2
CHEMBL482968	ENMD-2076	2
CHEMBL495727	AT-9283	2
CHEMBL513909	BI-2536	2
CHEMBL521851	PICTILISIB	2
CHEMBL564829	MILCICLIB	2
CHEMBL572878	TOZASERTIB	2
CHEMBL1084546	PF-00562271	1
CHEMBL1908397	KW-2449	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NAK family

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
compound 13 [PMID: 34333981]	Inhibition	7.09	pIC50
compound 6 [PMID: 34333981]	Inhibition	7.06	pIC50
STK16-IN-1	Inhibition	6.53	pIC50

Binding affinities (BindingDB)

7 measured of 7 human assays (7 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
PKC-412	KD	190 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
STK16-IN-1	IC50	7940 nM

ChEMBL bioactivities

105 potent at pChembl≥5 of 109 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.77	Kd	1.7	nM	R-406
8.18	Kd	6.6	nM	FEDRATINIB
7.96	Kd	11	nM	CHEMBL5633837
7.78	Kd	16.67	nM	CHEMBL5653589
7.75	Kd	18	nM	CHEMBL1908395
7.75	Kd	18	nM	NINTEDANIB
7.72	Kd	19	nM	LESTAURTINIB
7.63	ED50	23.15	nM	CHEMBL5653589
7.62	Kd	24	nM	CHEMBL516312
7.54	Kd	29	nM	KW-2449
7.11	Ki	78	nM	CHEMBL4571548
7.09	IC50	82	nM	CHEMBL5079149
7.07	Ki	86	nM	CHEMBL4470026
7.06	IC50	88	nM	CHEMBL5083125
7.04	Ki	91	nM	CHEMBL4534959
7.03	Kd	93.93	nM	CHEMBL3752910
7.02	Kd	95	nM	R-406
6.97	IC50	107	nM	CHEMBL4877883
6.96	Kd	110	nM	CHEMBL4576489
6.96	Ki	110	nM	CHEMBL4552310
6.88	ED50	130.4	nM	CHEMBL3752910
6.86	Kd	138	nM	PF-00562271
6.85	Kd	140	nM	JNJ-7706621
6.83	IC50	148	nM	CHEMBL5437375
6.82	Ki	150	nM	CHEMBL4542463
6.78	IC50	167	nM	CHEMBL187139
6.75	Ki	180	nM	CHEMBL4447403
6.75	Ki	180	nM	CHEMBL4582326
6.73	Kd	186	nM	CHEMBL3688339
6.70	Kd	200	nM	STAUROSPORINE
6.68	Kd	210	nM	CYC-116
6.66	Ki	220	nM	CHEMBL4472438
6.64	Kd	230	nM	CHEMBL1082152
6.63	IC50	235	nM	STAUROSPORINE
6.62	Ki	240	nM	CHEMBL4535040
6.62	IC50	242	nM	STAUROSPORINE
6.62	IC50	241	nM	STAUROSPORINE
6.60	Kd	250	nM	SUNITINIB
6.57	Ki	270	nM	CHEMBL4452939
6.57	Kd	270	nM	STAUROSPORINE
6.55	Kd	280	nM	MIDOSTAURIN
6.54	Ki	290	nM	CHEMBL4561238
6.53	Kd	295	nM	GILTERITINIB
6.51	Ki	310	nM	CHEMBL4531680
6.48	Ki	330	nM	CHEMBL4516665
6.46	Ki	350	nM	CHEMBL4452360
6.44	Kd	360	nM	SUNITINIB
6.44	Kd	365	nM	CHEMBL4465866
6.44	Kd	360	nM	PAZOPANIB
6.43	Kd	370	nM	AXITINIB

PubChem BioAssay actives

99 with measured affinity, of 836 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624775: Binding constant for STK16 kinase domain	kd	0.0017	uM
Fedratinib	624775: Binding constant for STK16 kinase domain	kd	0.0066	uM
2-[2-methyl-5-[3-(3,4,5-trimethoxyphenyl)-2H-pyrazolo[3,4-b]pyridin-5-yl]anilino]ethanol	2137777: Binding affinity to human STK16 assessed as dissociation constant by Adp-glo assay	kd	0.0110	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149509: Binding affinity to human STK16 incubated for 45 mins by Kinobead based pull down assay	kd	0.0167	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	624775: Binding constant for STK16 kinase domain	kd	0.0180	uM
5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide;hydrochloride	624775: Binding constant for STK16 kinase domain	kd	0.0180	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	508094: Binding affinity to STK16	kd	0.0190	uM
N-[5-(4-cyanophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide	389039: Binding affinity to human MPSK1	kd	0.0240	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624775: Binding constant for STK16 kinase domain	kd	0.0290	uM
N-[6-[3-(2-methylpropylsulfonylamino)phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.0780	uM
N-[3-[[5-bromo-4-[(4-sulfamoylphenyl)methylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide	1823769: Inhibition of human STK16 in presence of [gamma-33P-ATP] by radiometric scintillation assay	ic50	0.0820	uM
N-[6-[3-[[[ethyl(methyl)sulfamoyl]amino]methyl]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.0860	uM
4-[[[5-bromo-2-[3-(morpholin-4-ylmethyl)anilino]pyrimidin-4-yl]amino]methyl]benzenesulfonamide	1823769: Inhibition of human STK16 in presence of [gamma-33P-ATP] by radiometric scintillation assay	ic50	0.0880	uM
N-[6-[3-(cyclopropylmethylsulfonylamino)phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.0910	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149509: Binding affinity to human STK16 incubated for 45 mins by Kinobead based pull down assay	kd	0.0939	uM
8-[3-chloro-5-(1-methylindazol-5-yl)-2H-pyrazolo[3,4-b]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one	1769454: Inhibition of human wild type partial length STK16 (G11 to I305) expressed in bacterial expression system by Kinomescan method	ic50	0.1070	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526317: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged STK16 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.1100	uM
N-[6-[3-(propylsulfonylamino)phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.1100	uM
N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]-2-pyridinyl]methanesulfonamide	1425179: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1380	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435692: Binding constant for STK16 kinase domain	kd	0.1400	uM
2-[5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylphenyl]-1H-benzimidazole-4-carboxamide	1972173: Inhibition of MPSK1 (unknown origin) by Z’-Lyte kinase assay	ic50	0.1480	uM
N-[6-[3-[(cyclopropylmethylsulfonylamino)methyl]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.1500	uM
N-[6-[3-[(3,3,3-trifluoropropylsulfonylamino)methyl]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.1800	uM
N-[6-[3-[(2,2,2-trifluoroethylsulfonylamino)methyl]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.1800	uM
1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone	1425179: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1860	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	256606: Average Binding Constant for STK16; NA=Not Active at 10 uM	kd	0.2000	uM
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine	1425179: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2100	uM
N-[6-[3-[(diethylsulfamoylamino)methyl]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.2200	uM
3-[3-(2,3-dihydroxypropylamino)phenyl]-4-(5-fluoro-1-methylindol-3-yl)pyrrole-2,5-dione	465274: Inhibition of STK16	kd	0.2300	uM
N-[6-[3-(cyclobutylsulfonylamino)phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.2400	uM
Sunitinib	435692: Binding constant for STK16 kinase domain	kd	0.2500	uM
N-[6-[3-(diethylsulfamoylamino)phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.2700	uM
Midostaurin	435692: Binding constant for STK16 kinase domain	kd	0.2800	uM
N-[6-[3-[[[methyl(2,2,2-trifluoroethyl)sulfamoyl]amino]methyl]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.2900	uM
1-(4-fluoro-3-hydroxyphenyl)-7H-pyrrolo[2,3-h][1,6]naphthyridin-2-one	1801714: Invitrogen SelectScreen Enzymatic Assay from Article 10.1021/acschembio.6b00250: “Discovery of a Highly Selective STK16 Kinase Inhibitor.”	ic50	0.2950	uM
Gilteritinib	1425179: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2950	uM
N-[6-[3-[[ethyl(methyl)sulfamoyl]amino]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.3100	uM
N-[6-[3-(cyclopropylsulfonylamino)phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.3300	uM
N-[6-[3-(dimethylsulfamoylamino)phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.3500	uM
Pazopanib	435692: Binding constant for STK16 kinase domain	kd	0.3600	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526317: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged STK16 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.3650	uM
Axitinib	624775: Binding constant for STK16 kinase domain	kd	0.3700	uM
N-[6-[3-[(4-fluorophenyl)methylsulfonylamino]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.4300	uM
N-[6-[3-[(2-methylpropylsulfonylamino)methyl]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.4500	uM
(4-hydroxypiperidin-1-yl)-[4-[[4-[4-(3-methylsulfonylpropoxy)indol-1-yl]pyrimidin-2-yl]amino]cyclohexyl]methanone	769493: Binding affinity to STK16 (unknown origin)	kd	0.4500	uM
N-[6-[3-[(2-fluorophenyl)methylsulfonylamino]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.4700	uM
Ruxolitinib	624775: Binding constant for STK16 kinase domain	kd	0.4900	uM
Abemaciclib	1425179: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.4950	uM
N-[6-[3-[(3-fluorophenyl)methylsulfonylamino]phenyl]-1H-indazol-3-yl]cyclopropanecarboxamide	1547796: Displacement of Alexafluor labelled kinase tracer236 from biotinylated C-terminal Avi-tagged STK16 kinase domain (13 to 305 residues) (unknown origin) expressed in Escherichia coli measured after 1.5 hrs by TR-FRET assay	ki	0.5100	uM
14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one	256606: Average Binding Constant for STK16; NA=Not Active at 10 uM	kd	0.5100	uM

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, decreases expression	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, increases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
Cadmium Chloride	increases expression, decreases expression, increases abundance	2
GSK-J4	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
bisphenol A	decreases expression, increases methylation	1
beta-lapachone	increases expression	1
nickel sulfate	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
jinfukang	increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	decreases response to substance	1
Acrolein	increases oxidation, increases abundance, affects cotreatment	1
Amiodarone	increases expression	1
Atrazine	increases expression	1
Cadmium	increases abundance, increases expression	1
Lead	affects expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Quercetin	increases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Okadaic Acid	decreases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

ChEMBL screening assays

244 unique, capped per target: 244 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1020555	Binding	Inhibition of STK16 assessed as enzyme activity relative to control	Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). — J Med Chem

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3IF	Abcam HEK293T STK16 KO	Transformed cell line	Female
CVCL_TQ73	HAP1 STK16 (-) 1	Cancer cell line	Male
CVCL_TQ74	HAP1 STK16 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.